Eyelash Growth Drug Gets Panel Nod, Relying On Data From Use In Glaucoma
Executive Summary
Confident in the safety and efficacy data from 13 years of clinical development and post-marketing information on Allergan's glaucoma drug Lumigan, and well aware the new indication is not for medical use, the Dermatologic and Ophthalmic Drugs Advisory Committee unanimously favored approval of bimatoprost for eyelash growth stimulation Dec. 5